Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
10 Febbraio 2025 - 2:05PM
Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced the launch of its new corporate website.
The new site, which can be visited at www.avidbio.com, combines
Avid’s elevated brand story and visual identity with improved
functionality and navigation, all aimed at enhancing the visitor
experience, particularly for current and prospective customers.
The reimagined Avid website captures the
company’s elevated brand through the tagline, “Discover the Avid
effect.™”, helping educate visitors on the differentiation that
positions the company as one of the industry’s leading, most
trusted biologics CDMOs. It offers a completely revamped customer
experience highlighted by user-friendly navigation, improved
accessibility, video interaction, and educational resources.
“As a company that places the highest priority
on delivering exceptional quality service and exceeding the
expectations of our customers, we felt compelled to bring that same
ethos to our online presence,” said Nick Green, president and chief
executive officer of Avid. “We take great pride in unveiling our
new company website as a showcase to the Avid brand, capturing the
spirit of our team, our unrivaled expertise, world-class
facilities, and personalized process. For those that already have a
relationship with Avid, we expect the new site will align with
their experience. For those just getting to know us, we hope it
will serve as a trusted and valuable resource for exploration,
education, and engagement.”
About Avid Bioservices,
Inc.
Avid Bioservices (NASDAQ: CDMO) is a
dedicated contract development and manufacturing organization
(CDMO) focused on development and CGMP manufacturing of biologics.
The company provides a comprehensive range of process development,
CGMP clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With more than 30
years of experience producing biologics, Avid's services include
CGMP clinical and commercial drug substance manufacturing, bulk
packaging, release and stability testing and regulatory submissions
support. For early-stage programs the company provides a variety of
process development activities, including cell line development,
upstream and downstream development and optimization, analytical
methods development, testing and characterization. The scope
of our services ranges from standalone process development projects
to full development and manufacturing programs through
commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Grafico Azioni Avid Bioservices (NASDAQ:CDMO)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Avid Bioservices (NASDAQ:CDMO)
Storico
Da Feb 2024 a Feb 2025